[Federal Register: August 17, 2000 (Volume 65, Number 160)]
[Notices]
[Page 50206-50207]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr17au00-83]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by contacting Dennis Penn, at
the Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804;
telephone: 301/496-7056 ext. 211; fax: 301/402-0220; e-mail:
pennd@od.nih.gov. A signed Confidential Disclosure Agreement will be
required to receive copies of the patent applications.
Preparation and Use of Androgenic Compounds
Richard P. Blye and Hyun K. Kim (NICHD) DHHS Reference Nos. E-069-
00/0 filed 31 Mar 2000 and E-069-00/1 filed 04 Apr 2000.
The technology describes the finding of the orally active
androgenic compound, 7, 11-dimethyl-19-
nortestosterone 17-bucyclate (Also known as CDB-4386A). This 17-
bucyclate androgen compound is orally bioavailable and possesses
greater potency than Methyltestosterone, the only oral androgen
commercially available in this country. Too, this compound may be
injected as an aqueous suspension, whereas other injectable androgens
require an oil diluent. Androgens find use in the treatment of male
hypogonadism regardless of the cause. Consequently they are used for
the treatment of hypogonadotropic hypogonandism, as the androgenic
component of male hormonal contraceptives and for androgen
supplementation in hormone replacement therapy (HRT) in both men and
women.
Process for Preparing 17-Alpha-Acetoxy-11-Beta-[4-(N,N-
Dimethylamino)phenyl]-21-Methoxy-19-Norpregna-4,9-Diene-3,20-Dione,
Intermediates Useful in the Process, and Processes for Preparing
Such Intermediates
Hyun K. Kim (NICHD), and Pemmaraju Rao, James Cessac, and Anne
Marie Simmons of the Southwest Foundation for Biomedical Research DHHS
Reference No. E-013-00/0 filed 29 Dec 1999.
This invention relates to a process for preparing 17-alpha-acetoxy-
11-beta-[4-(N,N-dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-
diene-3,20-dione. This method substantially increases the yield over
existing methods and will substantially reduce the cost of production
of this compound. Other advantages include: (1) Use of smaller
quantities of solvent and reagent; (2) use of intermediates, reagents,
or byproducts which are relatively safe to handle and dispose of, no
use of chromatography; (3) a purification procedure easier to practice
on large scale from kilograms to multi-kilograms, including no use of
chromatography if possible; and (4) in some cases, recycling the by-
products was successfully achieved.
Novel Anti-thrombin Peptide From Mosquito Salivary Gland
Jesus G. Valenzuela, Jose M.C. Ribeiro, and Ivo Francischetti
(NIAID) DHHS Reference No. E-143-99/0 filed 29 Jun 1999.
Currently, treatment and prophylaxis of thrombotic diseases involve
therapeutic agents which act in one of two different ways. The first
type inhibits a-thrombin activity or a-thrombin formation, thus
preventing clot formation. The second category accelerates thrombolysis
and dissolves the blood clot, thereby removing it from the blood vessel
and unblocking the flow of blood. Heparin is an example of the first
class and is widely used; however, heparin is less effective in
treating patients with an anti-thrombin III deficiency. Hirudin is an
example of the second class of anti-thrombotic drugs.
This invention relates to an anti-thrombin (Anophelin) isolated
from the salivary glands of the mosquito Anopheles albimanus. The
purified peptide inhibits thrombin induced platelet aggregation,
thrombin esterolytic activity, and thrombin cleavage of fibrinogen.
This peptide has no homologies to proteins of known function in
GenBank, and is a novel, specific, and tight binding inhibitor of
-thrombin.
Ichthyosiform Skin Diseases
Peter M. Steinert, Nemes Zoltan and Lyuben Marckov (NIAMS) DHHS
Reference No. E-149-99/0 filed 23 Jun 1999.
Many inherited autosomal recessive ichthyoses (ARI) are caused by
improper or incomplete lipid barrier function in the skin due to
genetic errors of either protein or lipid synthesis. It is previously
known that the mutations in the transglutaminase 1 gene resulting in
inactive enzyme is the cause of one ARI disease termed lamellar
ichthyosis. This relates to the discovery that a principal function of
the enzyme is to attach ceramide lipids for complete protein/lipid
barrier function in the skin. This invention also describes how to: (1)
Make large quantities of this enzyme that can be stored in a stable
form which can be readied for use at short notice; (2) a simple way to
make synthetic ceramide lipid analogs that function the same way as
normal skin ceramides; and (3) make synthetic lipid vesicles that can
carry, in a stable fashion, both the enzyme and synthetic ceramide so
that it might be applied to affected ARI skin in order to provide
ameliorative therapy.
[[Page 50207]]
High Sensitivity Phage Display Protein Detection Method
Carl R. Merril (NIMH) DHHS Reference No. E-185-98/0 filed 14 Apr
1999.
This new technology extends the range of protein detection
appreciably under the absolute limit of 0.01ng for the Silver stain
method. In an average protein molecule this amounts to 20 million
molecules. The average cellular concentration of protein is 5000
molecules, so that an amplification system is needed to detect protein
on that level. In this method, phage that display specific ligands or
antibodies provide such an amplification system and therefore allow for
detection. In addition, a particular phage expressing a known binding
protein may be used to identify a specific protein and aid in the
purification of that specific protein. The identification ability has
both diagnostic and therapeutic potential.
The key novel feature of this technology in the market place would
be its high sensitivity and the numerous benefits associated with it.
It opens up whole new areas of analysis, such as on the cellular level,
allowing for looking at protein variations within a single cell.
Theoretically, as little as one protein molecule could be detectable.
The potential market for this invention would be in several
distinct areas: Research--incorporation into kits to perform complete
assays; Purification--aiding in the manufacturing process; Diagnostic--
detection of variations of a specific protein within a cell;
Therapeutic--identification of specific drug targets through the
ability to bind to receptor sites.
Dated: August 3, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 00-20922 Filed 8-16-00; 8:45 am]
BILLING CODE 4140-01-P